Hints and tips:
...Bayer, the German pharmaceutical and biotech company, in 2019 announced plans to move entirely to renewable energy....
...Within the commission Thierry Breton, the French commissioner for the EU’s internal market, has championed the push for European “strategic autonomy” in industries from pharmaceuticals and semiconductors...
...Sami Mahroum is a professor of management practice at Solvay Brussels School of Economics and Management....
...Other key fluoropolymer material makers include Solvay of Belgium, 3M of the US, Gujarat Fluorochemicals of India and HaloPolymer of Russia....
...The companies include Germany’s industrial conglomerate Siemens, pharmaceuticals company Bayer, Switzerland’s Nestlé, the world’s largest food producer by sales, and French oil group Total, which together...
...It is now more focused on producing chemical products for the pharmaceutical and cosmetic sectors....
...It comes ahead of a US Supreme Court decision on the case brought by the Federal Trade Commission against Solvay for payments to generic producers to delay rivals of its AndroGel product, with initial indications...
...The ruling provides a fresh twist to a dispute over efforts by Solvay, now part of AbbVie, to delay cut price versions of its AndroGel product following payments to generic rivals including Actavis....
...In Europe, the competition directorate gave the issue a new prominence in a pharmaceutical “sectoral inquiry” that warned such practices could violate EU law....
...The judgment came after the US Supreme Court this week paved the way for the Federal Trade Commission to scrutinise such deals, after a case involving Solvay (now part of AbbVie) and Actavis....
...was not “knee-jerk” but had been under consideration for several years and accelerated following the integration and internal separation within the group of the two divisions following its acquisition of Solvay...
...For example, Abbott Laboratories, which acquired a testosterone cream called Androgel when it bought the pharmaceuticals business of Belgian chemical company Solvay for $6bn in 2009, says worldwide sales...
...Family-controlled Solvay had been looking for an acquisition since September 2009, when it sold its pharmaceuticals arm to Abbott Laboratories for €4.5bn....
...Last month, Belgian chemicals company Solvay announced a €3.4bn bid for French rival Rhodia....
...Yet sales are so modest that Abbott, which acquired the drug last year when it bought the drug arm of Solvay, does not even list it as a product....
...Rights to the product were initially bought from its developer, Solvay, in 2008 by York Pharma for €28.5m (£24.2m)....
...He points to investments in Belgian companies such as Solvay, the pharmaceutical group, Quick, the burger chain that has spread to France, and Ijsboerke, an ice cream maker....
...Pharmaceuticals of Belgium....
...For Abbott, the Piramal transaction comes less than a year after it acquired the Belgium-based drugmaker Solvay for €4.5bn ($5.6bn), and follows the announcement last week of two collaboration agreements...
...Pfizer last year paid $68bn to acquire its smaller US rival Wyeth, while Abbott Laboratories of the US bought Solvay of Belgium’s pharmaceuticals business for $6.5bn....
...Many companies have sealed deals to expand through acquisitions – such as Abbott’s purchase of Solvay, a European company with a strong presence in emerging markets....
...Miles White, Abbott’s chairman and chief executive, said in a statement: “The acquisition of Solvay Pharmaceuticals further diversifies our pharmaceutical portfolio, expands our presence in key high-growth...
...Abbott Laboratories of the US has won the battle for Solvay of Belgium's pharamaceuticals business. Kevin Allison of Lex explains the rationale behind the deal....
...Solvay Pharmaceuticals had sales of €2.7bn last year....
...From the Chicago suburbs to the streets of Brussels, Abbott Laboratories’ €4.5bn cash acquisition of Solvay’s drugs business is the latest big pharmaceuticals deal....
International Edition